VH3810109

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

26 competitors in HIV Infections

#DrugCompanyPhaseTrials

1

Cabenuva

GSK

Phase 3

52

Tivicay

GSK

Phase 3

43

Biktarvy

Gilead

Phase 3

24

Sunlenca

Gilead

Phase 3

25

CAB LA

GSK

Phase 3

56

Fostemsavir

GSK

Phase 3

27

Rhuph20

Bristol-Myers Squibb

Phase 2

28

APRETUDE

GSK

Phase 3

19

Teropavimab

Gilead

Phase 3

110

Zinlirvimab

Gilead

Phase 3

1Show 8 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

HIV Infections2 trials

A Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion With rHuPH20, in Combination With CAB LA to Standard of Care in Virologically Suppressed Adults Living With HIV

Active, not recruiting·GSK·Phase 2·NCT05996471·185 enrolled

An Exploratory Phase 1b, Multicenter, Randomized, Open-Label Study to Investigate the Impact of the Administration of Intravenous VH3810109 With or Without Oral Fostemsavir in Combination With Integrase Inhibitor-Based Antiretroviral Therapy on the Viral Reservoir in Adults Living With HIV-1

Active, not recruiting·GSK·Phase 1·NCT07053384·130 enrolled

Intravenous1 trial

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

Completed·GSK·Phase 1·NCT05291520·24 enrolled

Details

Drug Info

Related News